Tandem Diabetes Care Q2 revenue slightly misses estimates
Tandem Diabetes Care Q2 revenue slightly misses estimates
Overview
Diabetes technology firm's Q2 revenue grew 6% but slightly missed analyst expectations
Gross margin rose to 57% from 52% a year earlier
Company narrowed net and operating losses from prior year
Outlook
Tandem Diabetes Care sees 2026 sales of $1.065 bln to $1.085 bln
Company expects 2026 gross margin of 56% to 57% of sales
Company expects 2026 adjusted EBITDA margin of 5% to 6% of sales
Result Drivers
PUMP SHIPMENTS - Co reported worldwide pump shipments of more than 33,000, including 22,000 in the U.S.
GROSS MARGIN IMPROVEMENT - Gross margin rose to 57%, up 460 basis points from Q2 2025
PAY-AS-YOU-GO MODEL - 10% of U.S. sales were through the pharmacy channel due to scaled pay-as-you-go reimbursement
Company press release: ID:nBwKjfVGa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Slight Miss* | $254.56 mln | $254.98 mln (20 Analysts) |
Q2 Loss Per Share |
| $0.31 |
|
Q2 Net Loss |
| $21.20 mln |
|
Q2 Gross Margin |
| 57.00% |
|
Q2 Operating income |
| -$13.80 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Tandem Diabetes Care, Inc. is $28.00, about 42.9% above its August 5 closing price of $19.59
Reuters Recommended Reads
Aug 5 - Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall
Aug 5 - LifeMD Q2 revenue misses estimates as shift to branded GLP-1 therapies weighs
Aug 5 - Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Tandem Diabetes Care
See all newsU.S. STOCKS ON THE MOVE -VF Corp, Biogen, AbbVie
US STOCKS ON THE MOVE-SpaceX, Humana, AbbVie
U.S. STOCKS ON THE MOVE-SpaceX, Humana, Crescent Energy
MedTech growth concerns likely to overshadow Q3 results, Leerink says
Tandem Diabetes Care, Inc. reports results for the quarter ended June 30 - Earnings Summary